Roche Reports Result of Tecentriq (atezolizumab) + Platinum-Based CT in P-III IMvigor130 Study for Advanced Bladder Cancer
Shots:
- involves assessing of Tecentriq + CT vs CT as monothx. in 1-213 patients with previously untreated LA or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy
- The P-III IMvigor130 study results: mPFS (8.2 vs 6.3mos.); median OS (16.0 vs 13.4 mos.); ORR (47.4% vs 43.8%); safety data of combination therapy is consistent with the safety profile of Tecentriq with no new safety signals
- Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1receptors- currently being evaluated in 4 P-III studies in combination with other therapies for early and advanced bladder cancer
Click here to read full press release/ article
Ref: Roche | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com